Oppenheimer Maintains Outperform on RxSight, Raises Price Target to $34
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Steven Lichtman maintains an Outperform rating on RxSight (NASDAQ:RXST) and raises the price target from $29 to $34.
August 08, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst has maintained an Outperform rating on RxSight and raised the price target from $29 to $34.
The raised price target by Oppenheimer indicates a positive outlook for RxSight. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100